PG
SAGE

PEAK6 Group’s Sage Therapeutics SAGE Stock Holding History

PEAK6 Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$46K Buy
+293
New +$46K ﹤0.01% 3941
2015
Q3 		– Sell
-2,757
Closed -$201K – 5523
2015
Q2 		$201K Buy
+2,757
New +$177K ﹤0.01% 3711

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Group's SAGE Position: Q2 2018 in Review

PEAK6 Group opened a new position in Sage Therapeutics (SAGE) in Q2 2018: 293 shares worth $46K. The stake represents ﹤0.01% of the portfolio and ranks #3941 among its holdings. This is a return to the name: PEAK6 Group previously reported a position in SAGE as recently as Q2 2015.

PEAK6 Group first reported a position in SAGE in Q2 2015 and has held it in 2 quarters since. The position peaked at $201K in Q2 2015. 268 funds tracked by Wall St. Rank hold SAGE as of Q2 2018.

  • PEAK6 Group held 293 shares of Sage Therapeutics worth $46K as of Q2 2018.
  • Sage Therapeutics was a new PEAK6 Group position in Q2 2018.
  • Sage Therapeutics made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #3941 holding.
  • PEAK6 Group first reported a position in Sage Therapeutics in Q2 2015 and has held it in 2 quarters since.
  • PEAK6 Group's Sage Therapeutics position peaked at $201K in Q2 2015.
  • 268 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.